CANF:NYE-Can-Fite BioPharma Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 1.89

Change

+0.06 (+3.28)%

Market Cap

USD 0.03B

Volume

0.69M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.07 (+0.10%)

USD160.13B 24.87 2.76
ADPT Adaptive Biotechnologies Corpo..

+0.95 (+2.02%)

USD6.19B 38.68 N/A
BHVN Biohaven Pharmaceutical Holdin..

+2.34 (+3.92%)

USD3.56B N/A N/A
ADCT ADC Therapeutics SA

-9.34 (-20.64%)

USD3.22B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+0.26 (+1.16%)

USD2.01B N/A N/A
ZYME Zymeworks Inc

+0.13 (+0.30%)

USD2.00B 300.20 N/A
RCUS Arcus Biosciences, Inc

-0.46 (-2.40%)

USD1.23B N/A N/A
KDMN Kadmon Holdings, Inc

-0.04 (-0.93%)

USD0.73B 2.20 N/A
CVM CEL-SCI Corporation

-0.05 (-0.37%)

USD0.52B N/A N/A
PFNX Pfenex Inc

+0.18 (+1.42%)

USD0.43B 268.67 63.90

ETFs Containing CANF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.73% 10% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.73% 10% F 14% F
Trailing 12 Months  
Capital Gain -23.17% 22% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.17% 22% F 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.88% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.88% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.84% N/A N/A N/A N/A
Risk Adjusted Return -39.38% N/A N/A N/A N/A
Market Capitalization 0.03B 9% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.10 70% C- 26% F
Price / Cash Flow Ratio -2.72 16% F 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -146.95% 33% F 2% F
Return on Invested Capital -616.80% 6% F 0% N/A
Return on Assets -73.23% 23% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.21 97% A+ 88% B+
Short Percent N/A N/A N/A N/A N/A
Beta 1.10 71% C- 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.